Biomarin Pharmaceutical (BMRN) Other Operating Expenses (2009 - 2026)

Biomarin Pharmaceutical's Other Operating Expenses history runs 18 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• Quarterly Other Operating Expenses rose 302.71% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (up 233.63% YoY) and the FY2025 annual result came in at $9.0 million, up 292.74% from the prior year.
• Other Operating Expenses was $4.0 million for Q1 2026 at Biomarin Pharmaceutical, up from $1.0 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $108.0 million in Q1 2022 and bottomed at -$121.5 million in Q4 2022.
• A 5-year average of -$2.5 million and a median of -$312000.0 in 2022 frame the typical range for Other Operating Expenses.
• Peak annual rise in Other Operating Expenses reached 22006.69% in 2022, while the deepest fall reached 1063.54% in 2022.
• Biomarin Pharmaceutical's Other Operating Expenses stood at -$121.5 million in 2022, then soared by 83.62% to -$19.9 million in 2023, then grew by 26.28% to -$14.7 million in 2024, then jumped by 106.99% to $1.0 million in 2025, then jumped by 286.44% to $4.0 million in 2026.
• Business Quant data shows BMRN's Other Operating Expenses at $4.0 million in Q1 2026, $1.0 million in Q4 2025, and $5.1 million in Q3 2025.